Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

OPKO Health acquires lead NK-1 compounds from Schering-Plough
December 2009
SHARING OPTIONS:

MIAMI—OPKO Health Inc. announced in November that it entered into an agreement to acquire assets relating to Schering-Plough's neurokinin-1 (NK-1) receptor antagonist program, which Schering-Plough is divesting in connection with its pending merger with Merck & Co. Inc. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications. Phase I clinical testing has also been initiated for a second compound in the same class. Closing of the transaction between OPKO and Schering-Plough is subject to completion of the merger.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.